ScienceBeam

ScienceBeam operates in the medical-device and neurotechnology segment, with an offering that spans electrophysiology recording, EEG and QEEG, neurofeedback, biofeedback, neuromodulation, brain mapping, and animal research. Its differentiation is breadth: the company combines recording hardware, stimulation devices, analysis software, and clinical or research workflows under the eWave, eStim2, eLab, and eLife product families. The eWave Pro system supports 32–128 channels for higher-resolution research, while other systems address lower-channel clinical, neurofeedback, and biofeedback use cases. That range allows ScienceBeam to serve laboratories, universities, hospitals, clinics, and educational settings without focusing on only one application. Larger established neurotechnology vendors may have greater visibility, regulatory scale, or distribution resources, while ScienceBeam’s apparent emphasis is an integrated and relatively broad product stack. The company’s Longgang, China base and stated international representative strategy suggest an export-oriented model, but geographic revenue mix and commercial scale remain unclear.

ScienceBeam’s trajectory appears to be built around product-line expansion rather than disclosed venture financing or rapid workforce scaling. Founded in 2000, the company has developed a portfolio covering conventional EEG and QEEG, advanced 32–128-channel research recording, neurofeedback and biofeedback, transcranial electrical stimulation, animal electrophysiology, and data-analysis software. Its products address both human and animal studies, broadening the potential research market beyond clinical neurodiagnostics. The company also states that its systems support more than 1,000 clinical and research centers, 10,000 trained professionals, and over 3,000 associated ISI publications, although the profile does not provide dates or independent validation for those figures. There are no disclosed funding rounds, acquisitions, valuation milestones, product-launch dates, or recent layoffs. Future growth therefore depends on evidence of regulatory approvals, channel expansion, recurring software adoption, and commercial traction that is not currently public.